Proteasome inhibition and its therapeutic potential in multiple myeloma

References

• AdamsJThe proteasome: a suitable antineoplastic targetNat Rev Cancer20044534936015122206
   PubMed Web of Science ®Google Scholar
• OrlowskiRZStinchcombeTEMitchellBSPhase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesJ Clin Oncol200220224420442712431963
   PubMed Web of Science ®Google Scholar
• AdamsJPotential for proteasome inhibition in the treatment of cancerDrug Discov Today20038730731512654543
   PubMed Web of Science ®Google Scholar
• Sanchez-SerranoISuccess in translational research: lessons from the development of bortezomibNat Rev Drug Discov20065210711416518378
   PubMed Web of Science ®Google Scholar
• AdamsJPalombellaVJSausvilleEAProteasome inhibitors: a novel class of potent and effective antitumor agentsCancer Res199959112615262210363983
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPChauhanDThe proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsCancer Res20016173071307611306489
   PubMed Web of Science ®Google Scholar
• LeBlancRCatleyLPHideshimaTProteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelCancer Res200262174996500012208752
   PubMed Web of Science ®Google Scholar
• LightcapESMcCormackTAPienCSChauVAdamsJElliottPJProteasome inhibition measurements: clinical applicationClin Chem200046567368310794750
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMExtended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood2007110103557356017690257
   PubMed Web of Science ®Google Scholar
• LeeSJRichardsonPGSonneveldPBortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyBr J Haematol2008143451151918986387
   PubMed Web of Science ®Google Scholar
• San-MiguelJFRichardsonPGSonneveldPEfficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 studyLeukemia200822484284918200040
   PubMed Web of Science ®Google Scholar
• ZangariMEsseltineDLeeCKResponse to bortezomib is associated to osteoblastic activation in patients with multiple myelomaBr J Haematol20051311717316173965
   PubMed Web of Science ®Google Scholar
• GiulianiNMorandiFTagliaferriSThe proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patientsBlood2007110133433817371942
   PubMed Web of Science ®Google Scholar
• TerposESezerOCroucherPDimopoulosMAMyeloma bone disease and proteasome inhibition therapiesBlood200711041098110417494860
   PubMed Web of Science ®Google Scholar
• ZangariMEsseltineDCavalloFPredictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patientsAm J Hematol200782983183317546639
   PubMed Web of Science ®Google Scholar
• MaMHYangHHParkerKThe proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agentsClin Cancer Res2003931136114412631619
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNaglerASonneveldPRandomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionJ Clin Oncol200725253892390117679727
   PubMed Web of Science ®Google Scholar
• BerensonJRYangHHVescioRASafety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-upAnn Hematol200887862363118463870
   PubMed Web of Science ®Google Scholar
• PopatROakerveeHWilliamsCBortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myelomaBr J Haematol2009144688789419183191
   PubMed Web of Science ®Google Scholar
• Pineda-RomanMZangariMvan RheeFVTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myelomaLeukemia20082271419142718432260
   PubMed Web of Science ®Google Scholar
• ReeceDEPizaGTrudelSA Phase I–II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone for Relapsed/Refractory Multiple MyelomaASH Annual Meeting Abstracts2006108113536
   Google Scholar
• KropffMBispingGSchuckEBortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaBr J Haematol2007138333033717614819
   PubMed Web of Science ®Google Scholar
• HajekRZahradovaLGregoraEThe reduced intensity Cvd regimen: a good option with well balanced efficacy/toxicity ratio for elderly patients with poor status performanceASH Annual Meeting Abstracts20081116112113699
   Google Scholar
• LeeSSSuhCKimBSBortezomib, doxorubicin and dexamethasone (PAD) combination therapy followed by thalidomide and dexamethasone (TD) as a salvage treatment for relapsed multiple myeloma (MM): preliminary analysis of efficacy and safetyASH Annual Meeting Abstracts2007110112731
   Google Scholar
• PalumboAGayFBringhenSBortezomib, doxorubicin and dexamethasone in advanced multiple myelomaAnn Oncol20081961160116518326520
   PubMed Web of Science ®Google Scholar
• RichardsonPJagannathSJakubowiakALenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II studyASH Annual Meeting Abstracts2008112111742
   Google Scholar
• PoenischWBourgeoisMWangSYBortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myelomaASH Annual Meeting Abstracts2007110112723
   Google Scholar
• PalumboAAmbrosiniMTBenevoloGBortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaBlood200710972767277217148584
   PubMed Web of Science ®Google Scholar
• TerposEHeathDJZervasKDimopoulosMAThe effect of bortezomib monotherapy and bortezomib-based regimens on bone metabolism in patients with relapsed/refractory multiple myelomaPaper presented at: Haematologica2007
   Google Scholar
• CiolliSLeoniFCasiniCBreschiCSantiniVBosiAThe addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myelomaBr J Haematol2008141681481918410447
   PubMed Web of Science ®Google Scholar
• KimYKLeeJJSohnSKClinical Efficacy of VEL-CTD (bortezomib, cyclophosphamide, thalidomide, and dexamethasone) regimen in patients with relapsed or refractory multiple myeloma: a phase II studyASH Annual Meeting Abstracts2008112113693
   Google Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• CavoMTacchettiPPatriarcaFSuperior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myelomaASH Annual Meeting Abstracts200811211158
   Google Scholar
• HarousseauJUpdated results: Randomized phase III IFM trial comparing Vel/Dex with VAD induction in MM in pts ≤ 65 yearsJoint ASH/ASCO Symposium200812
   Google Scholar
• SonneveldPvan der HoltBSchmidt-WolfIGHFirst analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (pad) vs vad as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)ASH Annual Meeting Abstracts200811211653
   Google Scholar
• Chanan-KhanASonneveldPSchusterMWAnalysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyJ Clin Oncol200826294784479018711175
   PubMed Web of Science ®Google Scholar
• VickreyEAllenSMehtaJSinghalSAcyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapyCancer2009115122923219090004
   PubMed Web of Science ®Google Scholar
• PourLAdamZBuresovaLVaricella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomibClin Lymphoma Myeloma20099215115319406726
   PubMedGoogle Scholar
• AsahiTTsutsuiMWakasugiMValacyclovir neurotoxicity: clinical experience and review of the literatureEur J Neurol200916445746019187258
   PubMed Web of Science ®Google Scholar
• HelldenALyckeJVanderTSvenssonJOOdar-CederlofIStahleLThe aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatmentJ Antimicrob Chemother200657594594916540518
   PubMed Web of Science ®Google Scholar
• MarinMGurisDChavesSSSchmidSSewardJFPrevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR Recomm Rep200762256RR-414017585291
   PubMedGoogle Scholar
• MiguelJFSSchlagRKhuagevaNKUpdated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myelomaASH Annual Meeting Abstracts1200811211650
   Google Scholar
• MateosMVOriolAMartinezJBortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent?ASH Annual Meeting Abstracts200811211651
   Google Scholar
• PalumboABringhenSRossiDA prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patientsASH Annual Meeting Abstracts1200811211652
   Google Scholar
• RosinolLCibeiraMTMartinezJThalidomide/dexamethasone (TD) vs bortezomib(Velcade(R))/thalidomide/dexamethasone (VTD) vs VBMCP/VBAD/Velcade(R) as induction regimens prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): first results of a prospective phase III PETHEMA/Gem trialASH Annual Meeting Abstracts200811211654
   Google Scholar
• AttalMHarousseauJLFaconTSingle versus double autologous stem-cell transplantation for multiple myelomaN Engl J Med2003349262495250214695409
   PubMed Web of Science ®Google Scholar
• CavoMTosiPZamagniEProspective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical studyJ Clin Oncol200725172434244117485707
   PubMed Web of Science ®Google Scholar
• RichardsonPLonialSJakubowiakALenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk Groups with updated results of a phase I/II studyASH Annual Meeting Abstracts20081121192
   Google Scholar
• HarousseauJLAttalMLeleuXBortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II studyHaematologica200691111498150517043025
   PubMed Web of Science ®Google Scholar
• CorsoABarbaranoLMangiacavalliSBortezomib with HIG-dose dexamethasone as first Line therapy in patients with multiple myeloma candidates to high-dose therapyASH Annual Meeting Abstracts2007110113595
   Google Scholar
• RosinolLOriolAMateosMVPhase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kineticsJ Clin Oncol200725284452445817785704
   PubMed Web of Science ®Google Scholar
• JagannathSDurieBGMWolfJLLong-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myelomaASH Annual Meeting Abstracts200610811796
   Google Scholar
• OrlowskiRZPetersonBLSanfordBBortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301ASH Annual Meeting Abstracts200610811797
   Google Scholar
• JakubowiakAKendallTAl-ZoubiAInitial treatment with bortezomib (Velcade(R)), Doxil(R), and dexamethasone (VDD) is superior to thalidomide and dexamethasone (TD) as initial therapy prior to autologous stem cell transplantation (ASCT) for multiple myeloma (MM)ASH Annual Meeting Abstracts2008112113713
   Google Scholar
• PalumboAFalcoPGayFBortezomib-doxorubicin-dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patientsASH Annual Meeting Abstracts200811211159
   Google Scholar
• BelchAReeceDEBahlisNJBortezomib [VELCADETM], pegylated liposomal doxorubicin [DOXIL/CAELYX(R)] and dexamethasone in the treatment of previously untreated multiple myeloma patients: impact on quality-of-lifeASH Annual Meeting Abstracts2007110113618
   Google Scholar
• LandauHHassounHCohenASequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (td) results in rapid control of untreated high-risk multiple myeloma (MM) and improves depth of responseASH Annual Meeting Abstracts2008112113712
   Google Scholar
• WangMGiraltSDelasalleKHandyBAlexanianRBortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myelomaHematology200712323523917558699
   PubMed Web of Science ®Google Scholar
• KaufmanJLGleasonCHeffnerLLonialSBortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myelomaASH Annual Meeting Abstracts2007110113605
   Google Scholar
• YoonSSKimHJChungJSSequential VAD (Vincristine, adriamycin, dexamethasone) and VTD (Bortezomib, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with bortezomib for newly diagnosed multiple myeloma: final analysis of phase II trialASH Annual Meeting Abstracts2008112113330
   Google Scholar
• BerensonJRYellinOWoytowitzDBortezomib, ascorbic acid and melphalan (bam) therapy for patients (pts) with newly diagnosed multiple myeloma (MM): an effective and well-tolerated frontline regimenASH Annual Meeting Abstracts2007110113602
   Google Scholar
• BensingerWJagannathSVescioRA phase II study of bortezomib (Velcade (R)), cyclophosphamide (Cytoxan(R)), thalidomide (Thalomid(R)) and dexamethasone as first-line therapy for multiple myelomaASH Annual Meeting Abstracts20081121194
   Google Scholar
• ReederCBReeceDEKukretiVCyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialLeukemia2009
   Web of Science ®Google Scholar
• KnopSLiebischPWandtHBortezomib, intravenous cyclophosphamide and dexamethasone (VelCD) for previously untreated multiple myeloma: an interim analysis of the German DSMM XIa TrialASH Annual Meeting Abstracts20081116112112776
   Google Scholar
• BarlogieBAnaissieEJShaughnessyJDJrNinety percent sustained complete response (CR) rate projected 4 years after onset of CR in gene expression profiling (GEP)-defined low-risk multiple myeloma (MM) treated with total therapy 3 (TT3): basis for GEP-risk-adapted TT4 and TT5ASH Annual Meeting Abstracts200811211162
   Google Scholar
• BarlogieBAnaissieEvan RheeFIncorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3Br J Haematol2007138217618517593024
   PubMed Web of Science ®Google Scholar
• MulliganGMitsiadesCBryantBGene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibBlood200710983177318817185464
   PubMed Web of Science ®Google Scholar
• HideshimaTMitsiadesCAkiyamaMMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood200310141530153412393500
   PubMed Web of Science ®Google Scholar
• QinJZZiffraJStennettLProteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cellsCancer Res200565146282629316024630
   PubMed Web of Science ®Google Scholar
• NikiforovMARiblettMTangWHTumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibitionProc Natl Acad Sci U S A200710449194881949318042711
   PubMed Web of Science ®Google Scholar
• JulligMZhangWVFerreiraAStottNSMG132 induced apoptosis is associated with p53-independent induction of pro-apoptotic NOXA and transcriptional activity of beta-cateninApoptosis200611462764116673057
   PubMed Web of Science ®Google Scholar
• Perez-GalanPRoueGVillamorNMontserratECampoEColomerDThe proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 statusBlood2006107125726416166592
   PubMed Web of Science ®Google Scholar
• FernandezYVerhaegenMMillerTPDifferential regulation of NOXA in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implicationsCancer Res200565146294630416024631
   PubMed Web of Science ®Google Scholar
• HideshimaTBradnerJEWongJSmall-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myelomaProc Natl Acad Sci U S A2005102248567857215937109
   PubMed Web of Science ®Google Scholar
• DavenportELMooreHEDunlopASHeat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cellsBlood200711072641264917525289
   PubMed Web of Science ®Google Scholar
• LeeAHIwakoshiNNAndersonKCGlimcherLHProteasome inhibitors disrupt the unfolded protein response in myeloma cellsProc Natl Acad Sci U S A2003100179946995112902539
   PubMed Web of Science ®Google Scholar
• ObengEACarlsonLMGutmanDMHarringtonWJJrLeeKPBoiseLHProteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsBlood2006107124907491616507771
   PubMed Web of Science ®Google Scholar
• LonialSWallerEKRichardsonPGRisk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaBlood2005106123777378416099887
   PubMed Web of Science ®Google Scholar
• JohnstonJAWardCLKopitoRRAggresomes: a cellular response to misfolded proteinsJ Cell Biol19981437188318989864362
   PubMed Web of Science ®Google Scholar
• PoruchynskyMSSackettDLRobeyRWWardYAnnunziataCFojoTProteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibitionCell Cycle20087794094918414063
   PubMed Web of Science ®Google Scholar
• CavalettiGGilardiniACantaABortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the ratExp Neurol2007204131732517214983
   PubMed Web of Science ®Google Scholar
• ArgyriouAAIconomouGKalofonosHPBortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literatureBlood200811251593159918574024
   PubMed Web of Science ®Google Scholar
• RichardsonPGBriembergHJagannathSFrequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibJ Clin Oncol200624193113312016754936
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWReversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelineBr J Haematol2009144689590319170677
   PubMed Web of Science ®Google Scholar
• Millennium Pharmaceuticals IVelcadeTM (bortezomib) for injectionPrescribing informationCambridge, MAMillennium Pharmaceuticals, Inc2005
   Google Scholar
• RavagliaSCorsoAPiccoloGImmune-mediated neuropathies in myeloma patients treated with bortezomibClin Neurophysiol2008119112507251218829381
   PubMed Web of Science ®Google Scholar
• RichardsonPGChanan-KhanALonialSTanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulationASH Annual Meeting Abstracts2007110111165
   Google Scholar
• JagannathSVijRStewartAKInitial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM)ASH Annual Meeting Abstracts200811211864
   Google Scholar
• VijRWangMOrlowskiRInitial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM)ASH Annual Meeting Abstracts200811211865
   Google Scholar
• PerroneGHideshimaTIkedaHAscorbic acid inhibits anti-tumor activity of bortezomib in vivoLeukemia2009
   Web of Science ®Google Scholar
• YangYKitagakiJWangHHouDXPerantoniAOTargeting the ubiquitin-proteasome system for cancer therapyCancer Sci20091001242819037995
   PubMed Web of Science ®Google Scholar
• SoucyTASmithPGMilhollenMAAn inhibitor of NEDD8-activating enzyme as a new approach to treat cancerNature2009458723973273619360080
   PubMed Web of Science ®Google Scholar
• PivaRRuggeriBWilliamsMCEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibBlood200811152765277518057228
   PubMed Web of Science ®Google Scholar
• WeberDBadrosAZJagannathSVorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experienceASH Annual Meeting Abstracts200811211871
   Google Scholar
• HanadaMSugawaraKKanetaKEpoxomicin, a new antitumor agent of microbial originJ Antibiot (Tokyo)19924511174617521468981
   PubMed Web of Science ®Google Scholar
• DemoSDKirkCJAujayMAAntitumor activity of PR-171, a novel irreversible inhibitor of the proteasomeCancer Res200767136383639117616698
   PubMed Web of Science ®Google Scholar
• AlsinaMTrudelSValloneMMolineauxCKunkelLGoyAPhase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignanciesASH Annual Meeting Abstracts200711011411
   Google Scholar
• FelingRHBuchananGOMincerTJKauffmanCAJensenPRFenicalWSalinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinosporaAngew Chem Int Ed Engl200342335535712548698
   PubMed Web of Science ®Google Scholar
• ChauhanDCatleyLLiGA novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomibCancer Cell20058540741916286248
   PubMed Web of Science ®Google Scholar
• HamlinPAAghajanianCHongDFirst-in-human phase 1 dose escalation study of NPI-0052, a novel proteasome inhibitor, in patients with lymphoma and solid tumorASH Annual Meeting Abstracts2008112114939
   Google Scholar
• PriceTPadrikPTownsendAClinical trial of NPI-0052 (2nd generation proteasome inhibitor) in patients having advanced malignancies with expanded RP2D cohorts in lymphoma and CLLASH Annual Meeting Abstracts2008112114934
   Google Scholar
• RichardsonPHofmeisterCCZimmermanTMPhase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myelomaASH Annual Meeting Abstracts2008112112770
   Google Scholar